Posted by Michael Wonder on 19 Dec 2024
Savara initiates rolling submission of a biologics license application to the US FDA for Molbreevi for the potential treatment of auto-immune pulmonary alveolar proteinosis
18 December 2024 - Company expects to complete BLA submission by end of Q1, 2025.
Savara has initiated a rolling submission of a BLA to the FDA for Molbreevi for the potential treatment of aPAP, a chronic and debilitating rare lung disease characterised by the abnormal build-up of surfactant in the alveoli of the lungs.
